Wealth Enhancement Advisory Services’s Ligand Pharmaceuticals LGND Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.01M	Buy	3,187 +489	+18%	+$115K	﹤0.01%	2065
2026 Q1	$538K	Buy	2,698 +10	+0.4%	+$1.98K	﹤0.01%	2259
2025 Q4	$527K	Buy	2,688 +78	+3%	+$15K	﹤0.01%	2436
2025 Q3	$478K	Buy	2,610 +6	+0.2%	+$892	﹤0.01%	2402
2025 Q2	$298K	Buy	2,604 +31	+1%	+$3.31K	﹤0.01%	2650
2025 Q1	$271K	Sell	2,573 -92	-3%	-$10.4K	﹤0.01%	2529
2024 Q4	$286K	Buy	+2,665	New	+$301K	﹤0.01%	2422

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wealth Enhancement Advisory Services's LGND Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Ligand Pharmaceuticals (LGND) stake by 18% in Q2 2026, buying an estimated $115K and bringing the position to 3,187 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #2065.

Wealth Enhancement Advisory Services first reported a position in LGND in Q4 2024 and has held it in 7 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Wealth Enhancement Advisory Services held 3,187 shares of Ligand Pharmaceuticals worth $1.01M as of Q2 2026.
Wealth Enhancement Advisory Services bought 489 Ligand Pharmaceuticals shares in Q2 2026, an estimated $115K.
Ligand Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #2065 holding.
Wealth Enhancement Advisory Services first reported a position in Ligand Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.